Loading news...
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) has earned an average rating of "Moderate Buy" from the fourteen analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company.
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company's long-term growth trajectory.
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations. Institutional and Insider Ownership 79.7% of Prelude
Campbell and CO Investment Adviser LLC lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 73.4% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 109,554 shares of the biotechnology company's stock after selling 302,964 shares during the quarter.
BioCryst Pharmaceuticals (NASDAQ: BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, highlighting continued momentum for its hereditary angioedema (HAE) franchise, a pending acquisition of Astria Therapeutics, and progress on an early-stage program for Netherton syndrome. 2025 described as a "transformative year" CEO Charlie Gayer said 2025 marked a turning point for the company,
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)–
NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET.
Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 14.6% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 3,092,592 shares of the biotechnology company's stock after selling 528,045 shares during the period. Assenagon Asset Management S.A. owned approximately
Alkeon Capital Management LLC lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 20.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,714,021 shares of the biotechnology company's stock after selling 1,500,000 shares during the quarter. Alkeon
The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.
– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock.
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to BioCryst's proposed acquisition of Astria Therapeutics, Inc. (the “Merger”).
Fisher Asset Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 8.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,782,489 shares of the biotechnology company's stock after selling 269,648 shares during the quarter. Fisher Asset
I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Profitability This table compares Merck KGaA and BioCryst
BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.